

Bioanalysis and Beyond

*Tony Edge
R&D Manager*

Red Bioforum, September 2017

Introduction

Review of current technologies

- Sample Handling
- Sample Preparation

Where are the challenges and drivers

- Ion Suppression
- Regulatory

What technologies are there today?

- Tubes, DBS

Technologies of the future that are available today

- CD
- Direct analysis

Let our imagination go wild




Current Technology – Sample Handling




Current Sampling Devices

PALL Pall Corporation



SHIMADZU



hemaPEN™ Workflow


TRAJAN



bmf
Boston Microfluidics



neoteryx™
The promise of microsampling, delivered



Current Sampling Devices

SeventhSense
BIOSYSTEMS




Tasso



HemaSpot™: Blood sampling device

Spot*On
SCIENCES



fluisense®




Agilent Technologies

Current Technology – Sample Preparation

Protein Precipitation

100µl of plasma + 300µl ACN

Centrifugation / filtration





SPE Phases

Reverse Phased

Mixed Mode




Liquid-Liquid Extraction



Other Approaches

Quechers



TFC




SLE, Ligand binding assays, immunodiagnosics, ultracentrifugation, ultrafiltration.....

Current Challenges


Collection of known sample volume





Collection of representative sample




Removal of matrix components



Current Challenges – Ion Suppression



Current Challenges – Matrix Removal



Current Challenges

Guidance for Industry

Bioanalytical Method Validation

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Brian Booth, 301-796-1508 or (CVM) John Kadavil, John.Kadavil@fda.hhs.gov

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Veterinary Medicine (CVM)

September 2013
Biopharmaceutics

Revision 1

HANDBOOK

GOOD LABORATORY PRACTICE (GLP)

Quality practices
for regulated non-clinical
research and development




UNDP/World Bank/WHO
Special Programme for Research and Training in Tropical Diseases (TDR)



Agilent Technologies

Analysis using a CD player

Feasible to etch a CD with channels and link to in built detector in CD player



Moving away from a Central Laboratory to Shops

Patients take their own samples



- Analysis done in 1-2 hours (c.f. old style photographs)
- Have central analytical laboratories



Taking Samples

- Miniaturisation


- 3D Printing of columns
- Miniature sample collection devices
- Integrate into a watch design



Tricorders – The Future of Bioanalysis?

Vital Technologies Corporation sold "Official Star-Trek Tricorder Mark 1"

- Comprised of clock, thermometer, barometer, colorimeter



Direct analysis

- Use of iPhone app
- MRI, DESI, MS, DART, LDTD

A futuristic, saucer-shaped spacecraft is shown flying over the horizon of Earth. The spacecraft is dark with a glowing blue and white underside, and two prominent red lights on its lower surface. The Earth's surface is visible in the foreground, showing blue oceans and white clouds. The background is a dark, starry space with a bright light source creating a lens flare effect.

We are bounded only by our imaginations